Amgen To Present At The 32nd annual Oppenheimer Healthcare Conference
Amgen will present virtually at the 32nd Annual Oppenheimer Healthcare Conference on March 16, 2022, at 11:20 a.m. ET. The presentation will be conducted by Rob Lenz, M.D., Ph.D., and Peter H. Griffith, focusing on Amgen's business developments. The webcast will be accessible to the public through Amgen's website, with an archive available for 90 days post-event. Amgen is a leading biotechnology firm, committed to improving health outcomes through innovative human therapeutics, and is recognized as one of the top sustainable companies globally.
- None.
- None.
THOUSAND OAKS, Calif., March 10, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will virtually present at the 32nd Annual Oppenheimer Healthcare Conference at 11:20 a.m. ET on Wednesday, March 16, 2022. Rob Lenz, M.D., Ph.D., senior vice president of Global Development and Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
The webcast, as with other selected presentations regarding developments in Amgen's business given at certain investor and medical conferences, can be accessed on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.
About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2021, Amgen was named one of the 25 World's Best Workplaces™ by Fortune and Great Place to Work™ and one of the 100 most sustainable companies in the world by Barron's.
For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.
CONTACT: Amgen, Thousand Oaks
Megan Fox, 805-447-1423 (media)
Michael Strapazon, 805-313-5553 (media)
Arvind Sood, 805-447-1060 (investors)
View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-to-present-at-the-32nd-annual-oppenheimer-healthcare-conference-301500534.html
SOURCE Amgen
FAQ
When will Amgen present at the Oppenheimer Healthcare Conference?
Who will represent Amgen at the conference?
How can I access Amgen's presentation at the Oppenheimer Healthcare Conference?
Will the Amgen conference presentation be available later?
What is Amgen's focus in biotechnology?
